Progress in Tumor Research最新文献_第9页

Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials. 环氧化酶-2抑制剂化疗治疗恶性疾病:临床前理论基础和临床试验的初步结果

Progress in Tumor Research Pub Date : 2003-01-01 DOI: 10.1159/000071376

Charles D Blanke, Jaime L Masferrer

引用次数: 4

Epidemiology of non-steroidal anti-inflammatory drugs and cancer. 非甾体抗炎药与癌症的流行病学。

Progress in Tumor Research Pub Date : 2003-01-01 DOI: 10.1159/000071364

John A Baron

{"title":"Epidemiology of non-steroidal anti-inflammatory drugs and cancer.","authors":"John A Baron","doi":"10.1159/000071364","DOIUrl":"https://doi.org/10.1159/000071364","url":null,"abstract":"<p><p>There is evidence that aspirin--and apparently other NSAIDs--may be protective agents against cancer in the gastrointestinal tract. These effects are particularly well documented in the colon and rectum. Even considered in isolation, the observational data regarding colorectal neoplasia are quite strong, and the reality of a protective effect is buttressed by clinical trial data showing that aspirin prevents sporadic adenomas. Furthermore, the NSAIDs sulindac celecoxib have actually led to the regression of existing colorectal polyps in patients with FAP. Clearly, NSAIDs have the potential to suppress carcinogenesis in the large bowel. Observational data suggesting inverse associations of NSAIDs with cancers of the stomach and esophagus have emerged from several case-control studies and a few cohort analyses. In some studies the findings display features often associated with causal relationships, for example decreasing risks with increasing doses or duration of use. Nonetheless, the data currently do not support a secure conclusion that NSAIDs protect against these malignancies. The relevant data are not nearly as extensive as those for the colorectum, and case-control investigation of these upper gastrointestinal sites may be particularly delicate. It is conceivable that early symptoms of cancer (or of pre-invasive lesions) may have discouraged NSAID use in the cancer patients, creating the appearance of a protective association of the drugs with the risk of these malignancies. More extensive observational data particularly from cohort studies would be desirable to confirm the existing findings and clarify the doses and durations of use required for an effect. Clinical trial investigation might also be practical for pre-neoplastic endpoints, or--in carefully selected populations--perhaps with cancer as the focus. There are only relatively limited data available regarding the effect of NSAIDs on cancer of the pancreas. However, the studies that have investigated this malignancy have reported indications that NSAIDs may have a protective effect. The effects of NSAIDs on cancers outside the gastrointestinal tract are not clear. Some investigations suggest that NSAID use, particularly aspirin, is inversely associated with risk of cancers of the breast or ovary, but several well-done studies have not seen these associations, and the observations could have been due to bias or confounding. Findings regarding prostate cancer are similarly conflicting. The urinary tract is one organ system in which several studies have reported an increased cancer risk in association with NSAID use. Nonetheless, the effects remain unclear. There is only limited available information regarding carcinoma of the bladder, and no firm conclusions can be drawn at this point. More extensive data have been generated regarding the effect of NSAIDs--largely salicylates--on renal cell carcinoma or cancer or the renal pelvis and ureter. Although some studies have reported in","PeriodicalId":49661,"journal":{"name":"Progress in Tumor Research","volume":"37 ","pages":"1-24"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000071364","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22427224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 168

Cyclooxygenase-2 in lung cancer. 环氧化酶-2在肺癌中的作用。

Progress in Tumor Research Pub Date : 2003-01-01 DOI: 10.1159/000071371

Steven M Dubinett, Sherven Sharma, Min Huang, Mariam Dohadwala, Mehis Pold, Jenny T Mao

引用次数: 52

Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. 非甾体抗炎和环氧化酶-2选择性抑制剂在临床癌症预防试验中的应用。

Progress in Tumor Research Pub Date : 2003-01-01 DOI: 10.1159/000071375

Ernest T Hawk, Jaye L Viner, Asad Umar

引用次数: 10

COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. COX-2抑制剂和其他非甾体抗炎药在膀胱癌和前列腺癌中的作用。

Progress in Tumor Research Pub Date : 2003-01-01 DOI: 10.1159/000071372

Anita L Sabichi, Scott M Lippman